Advanced Enzyme Technologies Limited (ADVENZYMES) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Advanced Enzyme Technologies Limited stock ₹310, price ₹282, upside +10.0%, quality 69 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range ₹217.73 – ₹538.10 · fair‑value band ₹192.68 – ₹483.47 · the ₹282.10 price screens below the ₹310.31 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Advanced Enzyme Technologies in your weekly email
Every Wednesday you see whether Advanced Enzyme Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally.
Show moreShow less
The company offers enzymes and probiotics-based nutritional supplements for human healthcare and nutrition, animal nutrition, fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications, biofuels, and bio-catalysis.
It also provides non-food processing enzymes for textile, leather, and pulp and paper processing, as well as detergents and cleaning aids. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005.
Advanced Enzyme Technologies Limited was founded in 1957 and is headquartered in Thane, India.
Stock analysis
Advanced Enzyme Technologies Limited (ADVENZYMES) currently trades at ₹282.10, while our model-based Fair Value estimate is ₹310.31, so the stock looks roughly fairly valued today (gap 9.1%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹267.47 per share, and 2 of the 26 models we run sit above the ₹282.10 price.
Bear case: the Dividend Discount group reads lowest at ₹61.60, and 24 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹192.68 (bear) to ₹483.47 (bull), the price of ₹282.10 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Basic Materials sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Advanced Enzyme Technologies Limited reported revenue of ₹7.5B in FY2026 versus ₹5.3B in FY2022, a compound +9.0%/yr. Reported net income was ₹1.7B in FY2026, compounding +9.0%/yr from FY2022.
Key figures
Market cap ₹31.6B (≈ $336M) Small · P/E ratio 18.5 · P/S ratio 4.04 · EPS (TTM) ₹15.25 · Dividend yield 0.5% · Net margin 21.9% · Return on equity 11.0% · Return on assets (EBIT) 10.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 71 out of 100 (medium confidence).
What moves the price
The share trades about 28% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −41% fair-value upside, at 10%, ADVENZYMES screens cheaper than that median.
Fair Value models
Bear₹192.68Fair Value ₹310.31Bull₹483.47
Price ₹282.10 · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹8.57 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+17.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.3%
Start year 2021 (pandemic). Over 10 years: +9.8% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.9%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+5.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.4%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5.4% vs 8.0%, steady
Profit margin 2020 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.40% → 25%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +12.5% a year for the price.
Compare Advanced Enzyme Technologies Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 756 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside+10.0% · Above median
Profitability
Return on equity (12 months)11.0% · Above median
Return on assets9.2% · Top 25%
Net margin (12 months)21.9% · Top 25%
Operating margin (12 months)28.5% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)16.2% · Above median
Dividend yield (12 months)0.5% · Bottom 25%
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/E (12 months)18.5× · Cheaper than median
P/B1.94× · Pricier than median
P/S (12 months)4.04× · Priciest 25%
Price / free cash flow (fiscal year)26.3× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Advanced Enzyme Technologies Limited (ADVENZYMES) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of ₹310.31 versus a price of ₹282.10, about +10% upside (fairly valued).
What is the fair value of ADVENZYMES?
Our model-based fair value for Advanced Enzyme Technologies Limited is ₹310.31 (as of Nov 9, 2026), built from audited fundamentals. The current price: ₹282.10.
What is the quality score of ADVENZYMES?
Advanced Enzyme Technologies Limited has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Advanced Enzyme Technologies Limited (ADVENZYMES)?
Our model-based price target is the fair value of ₹310.31 (as of Nov 9, 2026) from 26 valuation models. Cautious scenario ₹192.68, optimistic scenario ₹483.47. It is a calculation from audited fundamentals, not an analyst target.
What is the Advanced Enzyme Technologies Limited stock forecast for 2026?
Our models put fair value at ₹310.31, about +10% upside versus a price of ₹282.10 (fairly valued). Cautious scenario ₹192.68, optimistic scenario ₹483.47. The calculation is refreshed regularly with new filings.
What is the revenue of Advanced Enzyme Technologies Limited (ADVENZYMES)?
Advanced Enzyme Technologies Limited reported trailing-twelve-month revenue of about ₹7.8B (latest available figure, as of Nov 9, 2026).
Does Advanced Enzyme Technologies Limited pay a dividend?
Advanced Enzyme Technologies Limited currently shows a dividend yield of 0.48% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Advanced Enzyme Technologies Limited (ADVENZYMES) and when is the ex-dividend date?
Advanced Enzyme Technologies Limited pays a dividend of ₹1.35 per share a year, a dividend yield of 0.5%. The last ex-dividend date was Jul 24, 2026. A dividend has been paid every year since at least 2017. The payout ratio is 9.5% of earnings (on adjusted earnings, reported 8.9%). Free cash flow covers the dividend 8.26 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Advanced Enzyme Technologies Limited (ADVENZYMES)?
For today's price to be fair in a discounted-cash-flow model, Advanced Enzyme Technologies Limited would have to grow free cash flow by +17.2 % per year for five years (discount rate 12.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.3 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of ADVENZYMES use?
Our models discount Advanced Enzyme Technologies Limited at 12.7 %: a base by market capitalisation (small), damped by beta 0.68, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Advanced Enzyme Technologies Limited that is +17.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.7 %) and the same formula as our fair value.
How much growth has Advanced Enzyme Technologies Limited (ADVENZYMES) delivered so far?
Over the past 5 years revenue at Advanced Enzyme Technologies Limited grew +8.3 % a year. The price currently implies free-cash-flow growth of +17.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Advanced Enzyme Technologies Limited (ADVENZYMES) growing?
The median revenue growth in the sector is +8.7 % a year. That is the yardstick for the growth priced into Advanced Enzyme Technologies Limited (+17.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Advanced Enzyme Technologies Limited (ADVENZYMES)?
The free-cash-flow yield on the price is 3.81 %: that much free cash flow Advanced Enzyme Technologies Limited produces per unit of market value. When it exceeds the discount rate of our models (12.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Advanced Enzyme Technologies Limited (ADVENZYMES)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Advanced Enzyme Technologies Limited it is ₹310.31 per share (as of Nov 9, 2026), against a price of ₹282.10. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Advanced Enzyme Technologies Limited stock overvalued or undervalued in 2026?
As of Nov 9, 2026, ADVENZYMES trades below its calculated fair value: price ₹282.10, fair value ₹310.31, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ADVENZYMES?
No. The price is what the market pays today (₹282.10); the fair value is what the company's own numbers justify (₹310.31). For Advanced Enzyme Technologies Limited the two are ₹28.21 per share apart. That gap is exactly why we show both numbers side by side.
How much is Advanced Enzyme Technologies Limited worth?
The market values Advanced Enzyme Technologies Limited at about ₹31.6B (market capitalisation, as of Nov 9, 2026). Per share that is ₹282.10; our models calculate a fair value of ₹310.31 per share.
What do the bullish and bearish scenarios say about ADVENZYMES?
Our models span a range for Advanced Enzyme Technologies Limited: cautious scenario ₹192.68, base ₹310.31, optimistic ₹483.47 per share (as of Nov 9, 2026, price ₹282.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ADVENZYMES?
Advanced Enzyme Technologies Limited trades at a price-to-earnings ratio of 18.5 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹310.31 is built from several models across several years. Excluding one-off items of fiscal year 2026 it is 20.2 (reported for FY2026: 18.7). Median P/E at fiscal year-end, 9 fiscal years (2018 to 2026), reported earnings, FY2026 ex one-offs: 24.6. Other multiples: P/B 1.9, P/S 4.0, EV/EBITDA 13.5.
How solid is the balance sheet of Advanced Enzyme Technologies Limited (ADVENZYMES)?
Balance-sheet figures for Advanced Enzyme Technologies Limited (as of Nov 9, 2026): return on equity 11.0%, debt of 0.01 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is ADVENZYMES from its 52-week high?
Advanced Enzyme Technologies Limited trades at ₹282.10, about 28% below its 52-week high of ₹390.42 and 14% above the low of ₹248.35 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹310.31 is for.
Which stocks are comparable to Advanced Enzyme Technologies Limited?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Advanced Enzyme Technologies Limited stock attractive at the current price?
The data as of Nov 9, 2026: price ₹282.10, calculated fair value ₹310.31 (+10%), Quality Score 69/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ADVENZYMES calculated?
We run Advanced Enzyme Technologies Limited through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹310.31 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Advanced Enzyme Technologies Limited currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Advanced Enzyme Technologies Limited (ADVENZYMES)?
The closing price on Nov 9, 2026 was ₹282.10. Our model-based fair value is ₹310.31, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Advanced Enzyme Technologies Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹192.68 to ₹483.47) leaves room in how you read the outcome.
Where does the earnings growth of Advanced Enzyme Technologies Limited (ADVENZYMES) come from?
Earnings per share at Advanced Enzyme Technologies Limited grew +7.7 % a year from 2015 to 2026. Broken into its drivers: revenue per share +9.8 %, EBIT margin −5.2 %, tax rate +1.0 %, residual (interest, one-offs) +2.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Advanced Enzyme Technologies Limited
How large is the market capitalisation of Advanced Enzyme Technologies Limited (ADVENZYMES)?
The market capitalisation of Advanced Enzyme Technologies Limited is ₹31.6B (≈ $336M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Advanced Enzyme Technologies Limited (ADVENZYMES)?
The price-to-sales ratio of Advanced Enzyme Technologies Limited is 4.04 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Advanced Enzyme Technologies Limited (ADVENZYMES)?
Earnings per share at Advanced Enzyme Technologies Limited are ₹15.25 (price ÷ EPS = P/E 18.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Advanced Enzyme Technologies Limited (ADVENZYMES)?
The dividend yield of Advanced Enzyme Technologies Limited is 0.5% (payout 9.5%, on adjusted earnings, reported 8.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Advanced Enzyme Technologies Limited (ADVENZYMES)?
The net margin of Advanced Enzyme Technologies Limited is 21.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Advanced Enzyme Technologies Limited (ADVENZYMES)?
The return on equity (ROE) of Advanced Enzyme Technologies Limited is 11.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Advanced Enzyme Technologies Limited (ADVENZYMES)?
On an EBIT basis the return on assets of Advanced Enzyme Technologies Limited is 10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Advanced Enzyme Technologies Limited (ADVENZYMES)?
The operating margin of Advanced Enzyme Technologies Limited is 28.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Advanced Enzyme Technologies Limited (ADVENZYMES)?
Revenue at Advanced Enzyme Technologies Limited is growing +16.2% versus a year earlier (3y avg +11.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Advanced Enzyme Technologies Limited (ADVENZYMES)?
Earnings per share at Advanced Enzyme Technologies Limited are growing +11.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Advanced Enzyme Technologies Limited (ADVENZYMES) hold?
Advanced Enzyme Technologies Limited holds more cash than debt, ₹839M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Advanced Enzyme Technologies Limited in the live analysis
One click puts Advanced Enzyme Technologies Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026